Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis
First and only long-acting C5 inhibitor has demonstrated early onset and sustained clinical benefit, and may reduce treatment burden with dosing every 8 weeks.Improvement in activities of daily living seen across broad range of patients, including those with milder symptoms.Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This decision marks the first and only approval for a long-acting C5 complement inhibitor for